Bedaquiline-based Regimen (longer course)
Treatment for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: Bedaquiline 400mg daily for 2 weeks, then 200mg 3x/week for 22 weeks, combined with other second-line drugs for full duration
Effectiveness
80%
Safety Score
58%
Clinical Trials
50
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
Bedaquiline 400mg daily for 2 weeks, then 200mg 3x/week for 22 weeks, combined with other second-line drugs for full duration
Time to Effect
2-3 months for culture conversion
Treatment Duration
18-24 months
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$4,000
Side Effect Mgmt:$3,000
Total Annual:$22,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$90,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$26,829
Cost per Remission
$28,205
Comparison vs Injectable-containing MDR-TB regimen
Cost Difference
+$2,000/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Bedaquiline-based Regimen (longer course) Outcomes
for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+82%
Remission Rate
+78%
Common Side Effects
QT prolongation (Bedaquiline)
+15%
Hepatotoxicity
+8%
Nausea/Vomiting
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov